Tirzepatide (Mounjaro/Zepbound) — Expanded Indications

Type: drug

Status: Approved and widely available

Developer: Eli Lilly

Breakthrough Summary

Dual GIP/GLP-1 agonist now with expanded indications. GLP-1RA class associated with 27% lower cardiovascular risk across 39,394 patients. Weight loss does NOT cause disproportionate muscle loss.

Mechanism of Action

Dual GIP/GLP-1 receptor agonist with expanded indications for MASH, heart failure, sleep apnea, kidney disease

Year: 2025-2026